医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Boehringer Ingelheim invests to further develop the pet care market in China

2020年09月29日 PM05:00
このエントリーをはてなブックマークに追加


 

INGELHEIM, Germany

Boehringer Ingelheim has acquired an equity stake in China-based New Ruipeng Group (NRP Group). NRP Group is a fast-growing business that offers veterinary care, e-commerce and many other services to pet owners and the broader animal health market across China.

“Improving the health of animals and humans is what drives us in Boehringer Ingelheim. Strong collaborations and partnerships have always been key to achieving this goal,” commented Jean Scheftsik de Szolnok, Member of the Board of Managing Directors with responsibility for Animal Health. “Together with NRP Group and other partners we are looking forward to serving pet owners in China and contributing with our knowledge in areas such as disease understanding or training and education.”

China’s pet market is one of the fastest growing markets in the world. The number of pets is continuously rising as they play an increasingly significant role in people’s lives, and pet owners are looking for integrated online and offline products, services and information.

“We are committed to expanding our active role in this dynamic and fast-paced market. Along with NRP Group and our other partners, we believe we can advance animal health care in China to the benefit of our customers, our employees, our businesses, and most importantly, the pets,” shared David Gocken, Head of Animal Health for The Chinese Markets, Boehringer Ingelheim.

Through collaboration and knowledge sharing, the aim of the partnership with NRP Group is to offer better solutions, quality advice and professional care to the growing number of pets and pet owners across China.

This is an exciting milestone for the company’s business development in China. Boehringer Ingelheim will continue to invest in China and make its contributions to people’s aspirations for integrated and innovative solutions for their pets.

Boehringer Ingelheim remains fully committed to its current and future business partners, such as other clinics, veterinarians, distributors and animal health companies, and to expanding business opportunities with them. Both companies will continue to work independently according to their respective business models.

Through this investment, Boehringer Ingelheim joins a group of Chinese and overseas investors in NRP Group, including Tencent Holdings Ltd., a Chinese multinational technology company.

Please click on the link for ‘Notes to Editors’ and ‘References’: 
https://www.boehringer-ingelheim.com/press-release/partnership-further-develop-pet-market-china

View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005482/en/

CONTACT

Boehringer Ingelheim Animal Health Communication

Tereza Urbankova

552 16 Ingelheim, Germany

Phone: +49 6132 77 184817

Email: press@boehringer-ingelheim.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™